Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
21st Century Cures Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Education about Marathon Pharmaceuticals products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.
21st Century Cures Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.
21st Century Cures Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Issues Related to Duchenne Muscular Dystrophy. Issues Related to Precision Medicine in Rare Diseases Discussions related to the role of Marathon Pharmaceuticals, LLC as a rare disease company and the sale of legacy products.
American Cures Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.
American Cures Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.
American Cures Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Issues Related to Duchenne Muscular Dystrophy. Issues Related to Precision Medicine in Rare Diseases Discussions related to the role of Marathon Pharmaceuticals, LLC as a rare disease company and the sale of legacy products.
American Cures Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.
American Innovation and Competitiveness Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.
American Innovation and Competitiveness Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.
American Innovation and Competitiveness Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.
Advancing Hope Act of 2015
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to FDA product review. H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development; provisions related to the FDA product review. Discussions related to Marathon's Sale of Legacy Products,Precision Medicine and Education about Marathon's Initiatives and the role of Marathon Pharmaceuticals, LLC as a rare disease company
Advancing Hope Act of 2015
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program Implementation of P.L. 113-166 - Muscular Dystrophy Cures Act Reintroduction of the Dormant Therapies Act The Pediatric Rare Disease Priority Review Voucher Program Precision Medicine and related activities Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company
Advancing Hope Act of 2015
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program Implementation of P.L. 113-166 - Muscular Dystrophy Cures Act Reintroduction of the Dormant Therapies Act The Pediatric Rare Disease Priority Review Voucher Program Precision Medicine and related activities Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company
Advancing Hope Act of 2015
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program; Provisions supporting Precision Medicine and Education about Marathon's Initiatives. Discussions related to Marathon's Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company
Consolidated Appropriations Act, 2016
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
HR 2029 - Consolidated Appropriations Act of 2016; provisions related to FDA product review.
21st Century Cures Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program; Provisions supporting Precision Medicine and Education about Marathon's Initiatives. Discussions related to Marathon's Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company
21st Century Cures Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to FDA product review. H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development; provisions related to the FDA product review. Discussions related to Marathon's Sale of Legacy Products,Precision Medicine and Education about Marathon's Initiatives and the role of Marathon Pharmaceuticals, LLC as a rare disease company
Advancing Hope Act of 2016
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to FDA product review. H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development; provisions related to the FDA product review. Discussions related to Marathon's Sale of Legacy Products,Precision Medicine and Education about Marathon's Initiatives and the role of Marathon Pharmaceuticals, LLC as a rare disease company
Advancing Hope Act of 2016
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program; Provisions supporting Precision Medicine and Education about Marathon's Initiatives. Discussions related to Marathon's Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company
American Cures Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program; Provisions supporting Precision Medicine and Education about Marathon's Initiatives. Discussions related to Marathon's Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company
American Cures Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program Implementation of P.L. 113-166 - Muscular Dystrophy Cures Act Reintroduction of the Dormant Therapies Act The Pediatric Rare Disease Priority Review Voucher Program Precision Medicine and related activities Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company
American Cures Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to FDA product review. H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development; provisions related to the FDA product review. Discussions related to Marathon's Sale of Legacy Products,Precision Medicine and Education about Marathon's Initiatives and the role of Marathon Pharmaceuticals, LLC as a rare disease company
American Cures Act
Client: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC) · Firm: COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC)
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program Implementation of P.L. 113-166 - Muscular Dystrophy Cures Act Reintroduction of the Dormant Therapies Act The Pediatric Rare Disease Priority Review Voucher Program Precision Medicine and related activities Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company
No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
No specific provisions lobbied - General Support of passage for S. 3084 - American Innovation and Competitiveness Act, S. 289 - The American Cures Act and H.R. 6 - The 21st Century Cure Act Education about Marathon Pharmaceuticals future products (if approved by FDA). Education about Marathon Pharmaceuticals initiatives, role in rare diseases, precision medicine and sale of legacy products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Issues Related to Duchenne Muscular Dystrophy. Issues Related to Precision Medicine in Rare Diseases Discussions related to the role of Marathon Pharmaceuticals, LLC as a rare disease company and the sale of legacy products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to FDA product review. H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development; provisions related to the FDA product review. Discussions related to Marathon's Sale of Legacy Products,Precision Medicine and Education about Marathon's Initiatives and the role of Marathon Pharmaceuticals, LLC as a rare disease company
HR 2029 - Consolidated Appropriations Act of 2016; provisions related to FDA product review.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development, FDA reforms and the Pediatric Rare Disease Priority Review Voucher Program; Provisions supporting Precision Medicine and Education about Marathon's Initiatives. Discussions related to Marathon's Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program Implementation of P.L. 113-166 - Muscular Dystrophy Cures Act Reintroduction of the Dormant Therapies Act The Pediatric Rare Disease Priority Review Voucher Program Precision Medicine and related activities Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537 - The Advancing Hope Act, provisions related to the Pediatric Rare Disease Priority Review Voucher Program Implementation of P.L. 113-166 - Muscular Dystrophy Cures Act Reintroduction of the Dormant Therapies Act The Pediatric Rare Disease Priority Review Voucher Program Precision Medicine and related activities Sale of Legacy Products Role of Marathon Pharmaceuticals, LLC as a rare disease company
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing